Examkin

Soru

Zorluk: OrtaSubstance-Related and Addictive Disorders

A 38-year-old woman comes to the clinic seeking help to stop drinking alcohol. She reports consuming approximately half a bottle of wine every evening but expresses a strong desire to achieve total abstinence. She has been attending group counseling for the past month and feels motivated, but she requests medication to help manage her daily alcohol cravings. Her medical history is notable for opioid use disorder, which has been in sustained remission for the past 4 years on a stable dose of methadone. She has no other medical conditions. Vital signs are normal. Laboratory studies, including a comprehensive metabolic panel and complete blood count, are within normal limits. Which of the following is the most appropriate pharmacotherapy to promote alcohol abstinence in this patient?

  1. AcamprosateCevap
  2. B
    Naltrexone
  3. C
    Disulfiram
  4. D
    Buprenorphine
  5. E
    Lorazepam

Cevap

Acamprosate
The most appropriate pharmacotherapy for this patient is acamprosate. First-line pharmacological treatments for alcohol use disorder (AUD) include naltrexone and acamprosate. Naltrexone, a mu-opioid receptor antagonist, effectively reduces alcohol cravings and heavy drinking days. However, it is strictly contraindicated in patients who are currently taking opioid agonists (such as methadone or buprenorphine) or who have acute hepatitis or severe liver failure. Administering naltrexone to this patient, who is on methadone maintenance therapy, would immediately precipitate severe opioid withdrawal. Therefore, acamprosate is the correct choice. Acamprosate modulates glutamatergic transmission (acting as an NMDA receptor antagonist and GABA-A agonist) and is primarily cleared by the kidneys, making it safe for patients with liver disease or those on opioid therapy. It is highly effective for maintaining abstinence in motivated patients.

Adım Adım Çözüm

1
Identify the patient's primary clinical goal.
The patient is seeking pharmacotherapy to maintain abstinence from alcohol and reduce daily cravings.
Establishing the clinical goal (maintenance of abstinence versus acute withdrawal management) directs the choice of medication class.
2
Evaluate the patient's medical history for relevant contraindications.
The patient is actively taking methadone for opioid use disorder and has normal hepatic and renal function.
The first-line agents for alcohol use disorder include naltrexone and acamprosate, which have distinctly different contraindication profiles.
3
Select the appropriate first-line medication based on the patient's pharmacological profile.
Acamprosate is selected because naltrexone is strictly contraindicated in patients taking full opioid agonists.
Naltrexone is a mu-opioid antagonist and would precipitate severe acute opioid withdrawal if given to a patient on methadone. Acamprosate acts on glutamate and GABA systems and has no interaction with opioids.

Anahtar Kavram

Acamprosate is the preferred first-line pharmacotherapy for alcohol use disorder in patients who have contraindications to naltrexone, such as concurrent opioid agonist therapy or severe liver disease.
Bu soruyu puanla

Konular

Substance-Related and Addictive Disorders

Bu konudan daha fazla soru